Kiniksa Pharmaceuticals said first-quarter 2026 net product revenue for Arcalyst reached $214.3 million, up 56% from $137.8 million in the same period a year earlier.
Total revenue in the quarter was also $214.3 million, compared with $137.8 million in the first quarter of 2025. Net income rose to $22.6 million from $8.5 million a year ago.
Operating expenses increased to $185.0 million from $124.5 million. Cost of goods sold climbed to $20.8 million from $17.9 million. Collaboration expenses increased to $75.6 million from $43.8 million. Research and development spending rose to $27.5 million from $19.3 million. Selling, general and administrative expenses increased to $61.2 million from $43.5 million.
Cash, cash equivalents and short-term investments totaled $468.1 million at March 31, 2026, with no debt.
The company raised its 2026 Arcalyst net product revenue guidance to $930 million to $945 million, from a prior range of $900 million to $920 million.
On the commercial side, Kiniksa said more than 4,550 prescribers have written Arcalyst prescriptions for recurrent pericarditis since launch, and average therapy duration is approaching three years.
In the pipeline, Kiniksa said phase 2 data for KPL-387 in recurrent pericarditis are expected in the second half of 2026, with the phase 3 pivotal trial expected to begin by year-end. The company also expects to start a phase 1 first-in-human trial for KPL-1161 by the end of 2026. Today the company's shares have moved -0.6% to a price of $42.79. If you want to know more, read the company's complete 8-K report here.
